2024年

論文

消化器内科

英文
  1. A Novel Fluorescence-Based Leak Test Method for Rectal Anastomoses Using Aerosolized Indocyanine Green.
    Kondo A, Yokota N, Kobayashi N, Feng D, Asano E, Kumamoto K, Kobara H, Okano K.
    Dis Colon Rectum 67(1): 168-174, 2024
  2. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group.
    Liver Int 44(1): 113-124, 2024
  3. Involvement of essential trace elements in the pathogenesis of hepatitis C virus‑related chronic liver disease and nonalcoholic steatohepatitis.
    Himoto T, Fujita K, Mimura S, Tani J, Morishita A, Kubota S, Masaki T.
    Exp Ther Med 27(1): 19, 2024
  4. Simple use of Y-connector for proper positioning and contrast aspiration in biliary metal stent placement.
    Kobayashi K, Kobara H, Nomura T, Ogi T, Kamada H, Ono M, Masaki T.
    Endoscopy 56(S 01): E23-E24, 2024
  5. Alcohol-related cancer morbidity and mortality are stratified using modified albumin platelet product.
    Fujita K, Morishita A, Oura K, Ono M, Himoto T, Masaki T.
    Sci Rep 14(1): 1052, 2024
  6. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
    Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A.
    Target Oncol 19(1): 29-39, 2024
  7. Gait characteristics in patients with distal radius fracture using an in-shoe inertial measurement system at various gait speeds
    Yamamoto A, Fujita K, Yamada E, Ibara T, Nihey F, Inai T, Tsukamoto K, Kobayashi Y, Nakahara K, Okawa A.
    Gait Posture 107: 317-323, 2024
  8. Risk of map-like redness development after eradication therapy for Helicobacter pylori infection
    Matsumoto S, Sugimoto M, Fukuzawa M, Uesugi N, Iwata E, Kagawa Y, Madarame A, Koyama Y, Morise T, Uchida K, Yamaguchi H, Kono S, Naito S, Kawai T, Itoi T.
    Helicobacter in press
  9. Novel endoscopic duodenal observation protocol based on Seven Pictures Rule for detecting duodenal neoplasms during esophagogastroduodenoscopy: A prospective observational study.
    Kozuka K, Kobara H, Matsui T, Fujisawa A, Tatsuta M, Kobayashi M, Yasuda M, Nakatani K, Tada N, Chiyo T, Kobayashi N, Yachida T, Nishiyama N, Fujihara S, Kondo A, Okano K, Tsuji A, Masaki T.
    Dig Endosc 36(2): 154-161, 2024
  10. An Analysis of Delayed Bleeding in Cases of Colorectal Endoscopic Submucosal Dissection Due to Types of Direct Oral Anticoagulants in Japan.
    Yoshida N, Hayashi Y, Togo D, Oka S, Takada K, Fukunaga S, Morita Y, Hayashi T, Kozuka K, Tsuji Y, Murakami T, Yamamura T, Komeda Y, Takeuchi Y, Shinmura K, Fukuda H, Yoshii S, Ono S, Katsuki S, Kawashima K, Nemoto D, Yamamoto H, Saito Y, Tamai N, Iwao A, Itoi Y, Tsuji S, Inagaki Y, Inada Y, Soga K, Hasegawa D, Murakami T, Yoriki H, Fukumoto K, Motoyoshi T, Nakatani Y, Sano Y, Iguchi M, Fujii S, Ban H, Harada K, Okamoto K, Nishiyama H, Sasaki F, Mizukami K, Shono T, Shimoda R, Miike T, Yamaguchi N.
    Clin Gastroenterol Hepatol 22(2): 271-282, 2024
  11. Tumor-to-blood pool ratio of 18F-fluorodeoxyglucose-positron emission tomography’s standardized uptake value as a useful parameter indicating malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasm compared to the international Fukuoka guidelines: a retrospective cohort study from surgical resections.
    Suto H, Ando Y, Matsukawa H, Oshima M, Kamada H, Kobara H, Masaki T, Tanaka K, Norikane T, Nishiyama Y, Hirao T, Kumamoto K, Okano K.
    HPB (Oxford) 26(2): 291-298, 2024
  12. Current Trends on the Involvement of Zinc, Copper, and Selenium in the Process of Hepatocarcinogenesis.
    Himoto T, Masaki T.
    Nutrients  16(4): 472, 2024
  13. Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial)
    Takada K, Imai K, Yamada T, Ohata K, Kanesaka T, Nagami Y, Yamasaki Y, Kobara H, Inokuchi Y, Chino A, Yamaguchi S, Ikehara H, Kawamura T, Yabuuchi Y, Mizuguchi Y, Ikematsu H, Yokoi C, Hattori S, Ohno K, Yoshizawa Y, Fukuzawa M, Tsuji Y, Konishi J, Yamamura T, Osawa S, Oka S, Hikichi T, Togashi K, Hirasawa K, Uraoka T, Takeuchi Y, Chiba H, Komeda Y, Doyama H, Oba MS, Saito Y.
    BMC Gastroenterol 24(1): 69, 2024
  14. 18F-THK5351 Positron Emission Tomography Clearly Depicted Progressive Multifocal Leukoencephalopathy After Mantle Cell Lymphoma Treatment.
    Chiba Y, Kawakita R, Mitamura K, Takahashi K, Suzuki T, Nakamichi K, Suzuki K, Morishita A, Kobara H, Deguchi K, Masaki T.
    Intern Med in press
  15. Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study
    Suto H, Fuke T, Matsukawa H, Ando Y, Oshima M, Nagao M, Takahashi S, Shibata T, Yamana H, Kamada H, Kobara H, Okuyama H, Kumamoto K, Okano K.
    J Clin Med 13(5): 1216, 2024
  16. Higher Indocyanine Green Retention Is Associated with Improved Prognosis in Patients with Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization.
    Fujita K, Morishita A, Nakahara M, Ono M, Himoto T, Masaki T.
    J Vasc Interv Radiol 35(3): 428-436, 2024
  17. α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M.
    Int J Cancer 154(6): 1043-1056, 2024
  18. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study
    Suto H, Matsukawa H, Fuke T, Nagao M, Ando Y, Oshima M, Yamana H, Kamada H, Kobara H, Okuyama H, Kumamoto K, Okano K.
    Pancreatology 24(3): 431-436, 2024
  19. A Case of Idiopathic Portal Hypertension Diagnosed by Noninvasive Fibrosis Evaluation Using Elastography.
    Yano R, Tadokoro T, Morishita A, Ibuki E, Masaki T.
    Cureus 16(3): e56432
  20. Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data
    Suto H, Matsukawa H, Ando Y, Oshima M, Fuke T, Nagao M, Yamana H, Kamada H, Kumamoto K, Okano K.
    J Hepatobiliary Pancreat Sci in press
  21. IgG4-related pancreatobiliary diseases could be associated with onset of pancreatobiliary cancer: A multicenter cohort study
    Kurita Y, Kubota K, Fujita Y, Tsujino S, Sekino Y, Kasuga N, Iwasaki A, Iwase M, Izuka T, Kagawa K, Tanida E, Yagi S, Hasegawa S, Sato T, Hosono K, Kobayashi N, Ichikawa Y, Nakajima A, Endo I.
    J Hepatobiliary Pancreat Sci 31(3):173-182
  22. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab
    Katayama S, Iwata T, Kawada T, Okamoto Y, Sano Y, Kawago Y, Miyake S, Moriwake T, Kuinose A, Horikawa Y, Tsuboi K, Tsuboi I, Sakaeda K, Nakatsuka H, Takamoto A, Hirata T, Shirasaki Y, Yamasaki T, Morinaka H, Nagasaki N, Hara T, Ochi A, Okumura M, Watanabe T, Sekito T, Kawano K, Horii S, Yamanoi T, Nagao K, Yoshinaga K, Maruyama Y, Tominaga Y, Sadahira T, Nishimura S, Edamura K, Kobayashi T, Kusumi N, Kurose K, Yamamoto Y, Sugimoto M, Nakada T, Sasaki K, Takenaka T, Ebara S, Miyaji Y, Wada K, Kobayashi Y, Araki M.
    Urol Oncol 42(3):70.e11-70.e18
  23. Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Ductal Adenocarcinoma.
    Nagao M, Oshima M, Suto H, Sugimoto M, Enomoto A, Murakami T, Shimomura A, Wada Y, Matsukawa H, Ando Y, Kishino T, Kumamoto K, Kobara H, Kamada H, Masaki T, Soga T, Okano K.
    Pancreas 53(4): e301-e309, 2024
  24. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
    Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
    Hepatol Res 54(4): 382-391, 2024
  25. Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study.
    Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
    Clin Mol Hepatol 30(2): 225-234, 2024
  26. Clinical outcomes of the over-the-scope clip closure after duodenal endoscopic submucosal dissection: A multicenter retrospective study
    Fukui H, Dohi O, Hirose T, Furukawa K, Tashima T, Tada N, Ichinona T, Asai S, Kobara H, Itoh Y.
    J Gastroenterol Hepatol 39(4): 725-732, 2024
  27. Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients
    Tadokoro T, Nomura T, Fujita K, Manabe T, Takuma K, Nakahara M, Oura K, Mimura S, Tani J, Morishita A, Kobara H, Ono M, Masaki T.
    BMC Gastroenterol 24(1): 123, 2024
  28. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
    Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
    Clin Gastroenterol Hepatol 22(4): 789-797, 2024
  29. Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
    Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M.
    Liver Cancer 13(5): 522-536, 2024
  30. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, Toyoda H, Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T; Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group).
    Cancer Rep (Hoboken) 7(4): e2042, 2024
  31. Effects of D-allose on ATP production and cell viability in neonatal rat cardiomyocytes.
    Chen X, Rahman A, Akumwami S, Morishita A, Kitada K, Ikeda Y, Funamoto M, Nishiyama A.
    J Pharmacol Sci 154(4): 274-278, 2024
  32. ological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021.
    Enomoto H, Akuta N, Hikita H, Suda G, Inoue J, Tamaki N, Ito K, Akahane T, Kawaoka T, Morishita A, Ogawa E, Tateishi R, Yoshiji H.
    Hepatol Res 54(8): 763-772, 2024
  33. Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022
    Okizaki A, Nishiyama Y, Inui Y, Otsuka H, Takanami K, Nakajo M, Nakatani K, Nogami M, Hirata K, Maeda Y, Yoshimura M, Wakabayashi H.
    Ann Nucl Med 38(4):315-327, 2024
  34. A combined score for predicting clinically relevant postoperative pancreatic fistula based on inflammatory parameters and drainage fluid culture results on postoperative day 3.
    Suto H, Matsukawa H, Ando Y, Oshima M, Fuke T, Norikane T, Sanomura T, Kamada H, Kobara H, Masaki T, Kumamoto K, Okano K.
    World J Surg 24(1): 123, 2024
  35. Severe induction of aberrant DNA methylation by nodular gastritis in adults
    Sasaki A, Takeshima H, Yamashita S, Ichita C, Kawachi J, Naito W, Ohashi Y, Takeuchi C, Fukuda M, Furuichi Y, Yamamichi N, Ando T, Kobara H, Kotera T, Itoi T, Sumida C, Hamada A, Koizumi K, Ushijima T.
    J Gastroenterol in press
  36. Effectiveness of edoxaban in portel vein thrombosis associated with liver cirrhosis.
    Tadokoro T, Tani J, Manabe T, Takuma K, Nakahara M, Oura K, Mimura S, Fujita K, Nomura T, Morishita A, Kobara H, Himoto T, Ono M, Masaki T.
    Sci Rep 14(1): 10784, 2024
  37. Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
    Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Soldà C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F.
    Liver Int (5): 1108-1125, 2024
  38. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
    Suto H, Matsukawa H, Fuke T, Nagao M, Ando Y, Oshima M, Yamana H, Kamada H, Kobara H, Okuyama H, Kumamoto K, Okano K.
    Pancreatology 24(3): 431-436, 2024
  39. A combined score for predicting clinically relevant postoperative pancreatic fistula based on inflammatory parameters and drainage fluid culture results on postoperative day 3.
    Suto H, Matsukawa H, Ando Y, Oshima M, Fuke T, Norikane T, Sanomura T, Kamada H, Kobara H, Masaki T, Kumamoto K, Okano K.
    World J Surg 48(5): 1231-1241, 2024
  40. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
    Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group.
    Aliment Pharmacol Ther  60(2): 233-245, 2024
  41. A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up.
    Mimura S, Ono M, Fujita K, Takuma K, Nakahara M, Oura K, Tadokoro T, Tani J, Morishita A, Kagawa S, Okano K, Himoto T, Masaki T.
    Intern Med in press

  42. A rare case of hypervirulent Klebsiella pneumoniae liver abscess and bacterial endophthalmitis associated with distal bile duct cancer
    Ando Y, Matsukawa H, Suto H, Oshima M, Snomura H, Kamada H, Kumamoto K, Yokota K, Suzuki Y, Okano K.
    Clin J Gastroenterol 17(4):731-736, 2024
  43. Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data
    Suto H, Matsukawa H, Ando Y, Oshima M, Fuke T, Nagao M, Yamana H, Kamada H, Kumamoto K, Okano K.
    J Hepatobiliary Pancreat in press
  44. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
    Tsutsumi T, Kawaguchi T, Fujii H, Kamada Y, Takahashi H, Kawanaka M, Sumida Y, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Nakajima A, Okanoue T.
    Aliment Pharmacol Ther 59(12): 1559-1570, 2024
  45. Chronic activation of β-adrenergic receptors leads to tissue water and electrolyte retention.
    Akumwami S, Kitada K, Fujisawa Y, Kundo NK, Rahman MM, Morishita A, Kitamura H, Rahman A, Ogino Y, Nishiyama A.
    J Pharmacol Exp Ther JPET-AR-2024-002185, 2024
  46. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
    Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T.
    Oncol Lett 28(2):397, 2024
  47. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
    Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A.
    Target Oncol 19(4):645-659, 2024
  48. Fusobacterium species are distinctly associated with patients with Lynch syndrome colorectal cancer
    Salim F, Mizutani S, Shiba S, Takamaru H, Yamada M, Nakajima T, Yachida T, Soga T, Saito Y, Fukuda S, Yachida S, Yamada T.
    iScience 27(7):110181, 2024
  49. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey
    Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, Shiraki M, Ohnishi H, Yasumura J, Kawabe T, Miyamae T, Matsubara T, Arakawa N, Ishige T, Takizawa T, Shimbo A, Shimizu M, Kimura N, Maeda Y, Maruyama Y, Shigemura T, Furuta J, Sato S, Tanaka H, Izumikawa M, Yamamura M, Hasegawa T, Kaneko H, Nakagishi Y, Nakano N, Iida Y, Nakamura T, Wakiguchi H, Hoshina T, Kawai T, Murakami K, Akizuki S, Morinobu A, Ohmura K, Eguchi K, Sonoda M, Ishimura M, Furuno K, Kashiwado M, Mori M, Kawahata K, Hayama K, Shimoyama K, Sasaki N, Ito T, Umebayashi H, Omori T, Nakamichi S, Dohmoto T, Hasegawa Y, Kawashima H, Watanabe S, Taguchi Y, Nakaseko H, Iwata N, Kohno H, Ando T, Ito Y, Kataoka Y, Saeki T, Kaneko U, Murase A, Hattori S, Nozawa T, Nishimura K, Nakano R, Watanabe M, Yashiro M, Nakamura T, Komai T, Kato K, Honda Y, Hiejima E, Yonezawa A, Bessho K, Okada S, Ohara O, Takita J, Yasumi T, Nishikomori R; Japan CAPS Working Group.
    Arthritis Rheumatol 76(6):949-962, 2024
  50. Response to Zhong et al.
    Nishiyama N, Kobara H.
    Endoscopy 56(7): 550-551, 2024
  51. Cecum-limited lschemic Colitis.
    Fujihara S, Nishiyama N, Kobara H.
    Intern Med in press
  52. Treatment of Hepatocellular Carcinoma with Major Vascular Invasion
    Tadokoro T, Tani J, Morishita A, Fujita K, Masaki T, Kobara H.
    Cancers 16(14):2534, 2024
  53. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
    Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group.
    Aliment Pharmacol Ther 60(2): 233-245, 2024
  54. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
    Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A.
    Target Oncol 19(4): 645-659, 2024
  55. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021.
    Enomoto H, Akuta N, Hikita H, Suda G, Inoue J, Tamaki N, Ito K, Akahane T, Kawaoka T, Morishita A, Ogawa E, Tateishi R, Yoshiji H.
    Hepatol Res 54(8): 763-772, 2024
  56. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    Atsukawa M, Tsubota A, Kondo C, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Morishita A, Tani J, Okubo H, Hiraoka A, Nozaki A, Chuma M, Kawata K, Uojima H, Ogawa C, Asano T, Mikami S, Kato K, Matsuura K, Ikegami T, Ishikawa T, Tsuji K, Tada T, Tsutsui A, Senoh T, Kitamura M, Okubo T, Arai T, Kohjima M, Morita K, Akahane T, Nishikawa H, Iwasa M, Tanaka Y, Iwakiri K.
    J Gastroenterol 59(12): 1559-1570
  57. Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis.
    Hatanaka T, Saito N, Kakizaki S, Hiraoka A, Tada T, Kariyama K, Tani J, Takaguchi K, Itobayashi E, Ishikawa T, Toyoda H, Kawata K, Naganuma A, Yata Y, Ohama H, Matono T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Nakamura S, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group.
    Oncology 20: 1-13, 2024
  58. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.
    Fujita K, Yamada M, Morishita A, Ono M, Himoto T, Kobara H, Masaki T.
    Biochem Pharmacol 226: 116321, 2024
  59. Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis.
    Hatanaka T, Saito N, Kakizaki S, Hiraoka A, Tada T, Kariyama K, Tani J, Takaguchi K, Itobayashi E, Ishikawa T, Toyoda H, Kawata K, Naganuma A, Yata Y, Ohama H, Matono T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Nakamura S, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group.
    Oncology 20: 1-13, 2024
  60. 18F-THK5351 Positron Emission Tomography Clearly Depicted Progressive Multifocal Leukoencephalopathy after Mantle Cell Lymphoma Treatment.
    Chiba Y, Kawakita R, Mitamura K, Takahashi K, Suzuki T, Nakamichi K, Suzuki K, Morishita A, Kobara H, Deguchi K, Masaki T.
    Intern Med 63(16): 2325-2329, 2024
  61. Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants
    Kamada Y, Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe C, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito Y, Takahashi H, Sumida Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
    Gastro Hep Adv 3(8): 1148-1156, 2024
  62. WONDER-02: plastic stent vs. lumen-apposing metal stent for endoscopic ultrasound-guided drainage of pancreatic pseudocysts-study protocol for a multicentre randomised non-inferiority trial
    Saito T, Takenaka M, Kuwatani M, Doi S, Ohyama H, Fujisawa T, Masuda A, Iwashita T, Shiomi H, Hayashi N, Iwata K, Maruta A, Mukai T, Matsubara S, Hamada T, Inoue T, Matsumoto K, Hirose S, Fujimori N, Kashiwabara K, Kamada H, Hashimoto S, Shiratori T, Yamada R, Kogure H, Nakahara K, Ogura T, Kitano M, Yasuda I, Isayama H, Nakai Y; WONDERFUL study group in Japan and collaborators.
    Trials 25(1):559, 2024
  63. Dynamics of the gut microbiome in FAP patients undergoing intensive endoscopic reduction of polyp burden
    Mizutani S, Tamaki A, Shiba S, Salim F, Yamada M, Takamaru H, Nakajima T, Yoshida N, Ikuta S, Yachida T, Shibata T, Soga T, Saito Y, Fukuda S, Ishikawa H, Yamada T, Yachida S.
    Gut 1: gutjnl-2024-332381, 2024
  64. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.
    Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, Kulthamrongsri N, Jaisa-Aad M, Ng CH, Teng M, Nakano M, Morishita A, Alkhouri N, Yang JD, Chen VL, Kim D, Fallon MB, Diaz LA, Arab JP, Mantzoros CS, Noureddin M, Lazarus JV, Wijarnpreecha K.
    Metabolism 158:155958, 2024
  65. Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals.
    Tani J, Masaki T, Oura K, Tadokoro T, Morishita A, Kobara H.
    Microorganisms 12(9): 1926, 2024
  66. Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
    Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group.
    PLoS One 19(9): e0311084, 2024
  67. New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map
    Okuyama C, Higashi T, Ishizu K, Oishi N, Kusano K, Ito M, Kagawa S, Okina T, Suzuki N, Hasegawa H, Nagahama Y, Watanabe H, Ono M, Yamauchi H.
    Ann Nucl Med 30(2): 225-234, 2024
  68. Tenascin-X is increased with decreased expression of miR-378a-5p and miR-486-5p in mice fed a methionine-choline-deficient diet that induces hepatic fibrosis
    Matsumoto K, Higuchi T, Umeki M, Ono M, Sakamoto S.
    Biomed Res 45(2):67-76, 2024
  69. Rebleeding Risk of Acute Hemorrhagic Rectal Ulcer: A Multicenter Retrospective Study
    Muramatsu T, Fukuzawa M, Madarame A, Kagawa Y, Kikuchi M, Taniguchi S, Shimai S, Matsumoto S, Yamanishi F, Suzuki Y, Nemoto D, Shinohara H, Matsumoto T, Koyama Y, Uchida K, Yamaguchi H, Morise T, Sugimoto A, Yamauchi Y, Kono S, Naito S, Nakamura H, Nutahara D, Matsue Y, Kishimoto Y, Yamamoto K, Kawai T, Itoi T.
    Intern Med 63(18):2481-2490, 2024
  70. Bone marrow edema detection for diagnostic support of axial spondyloarthritis using MRI
    Kojima A, Tomita T, Tsuji S, Kadono Y, Tada K, Nozaki T, Tamaki M, Koyama Y, Dobashi H, Okano T, Kawaai S, Atsumi T, Tamura N, Matsumoto Y, Goto H, Taniguchi Y, Ueki Y, Takagi M, Matsui K, Hagimori K, Shimizu A.
    Int J Comput Assist Radiol Surg 19(9):1699-1711, 2024
  71. Prevalence of Chronic liver disease in Cholangiocarcinoma: a Meta-Analysis
    Tham EKJ, Lim RY, Koh B, Tan DJH, Ng CH, Law M, Cho E, Tang NSY, Tan CS, Sim BKL, Tan EY, Lim WH, Lim MC, Nakamura T, Danpanichkul P, Chirapongsathorn S, Wijarnpreecha K, Takahashi H, Morishita A, Zheng MH, Kow A, Muthiah M, Law JH, Huang DQ.
    Clin Gastroenterol Hepatol 1542-3565(24)00971-6, 2024
  72. Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease.
    Nouso K, Kawanaka M, Fujii H, Kariyama K, Toyoda H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Kumada T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD).
    Hepatol Res 54(10): 912-920, 2024
  73. Liver Cancer in 2021: Global Burden of Disease Study.
    Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, Koh B, Lim RYZ, Tham EKJ, Mitra K, Morishita A, Hsu YC, Yang JD, Takahashi H, Zheng MH, Nakajima A, Ng CH, Wijarnpreecha K, Muthiah MD, Singal AG, Huang DQ.
    J Hepatol in press
  74. Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
    Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M.
    Oncology 11: 1-13, 2024
  75. Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up.
    Ogawa Y, Tomeno W, Imamura Y, Baba M, Ueno T, Kobayashi T, Iwaki M, Nogami A, Kessoku T, Honda Y, Notsumata K, Fujikawa H, Kaai M, Imajo K, Kawanaka M, Hyogo H, Hisatomi M, Takeuchi M, Hakamada T, Honda T, Tatsuta M, Morishita A, Mikami S, Furuya K, Manabe N, Kamada T, Kawaguchi T, Yoneda M, Saito S, Nakajima A.
    Hepatol Res in press
  76. Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice.
    Tomonari T, Tani J, Sato Y, Tanaka H, Morishita A, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T.
    JGH Open 8(10): e70033, 2024
  77. Overall Survival of Young Patients with Hepatocellular Carcinoma in Barcelona Clinic Liver Cancer Stage B in a Retrospective Study Based on a Multicenter Cohort.
    Fujita K, Oura K, Morishita A, Himoto T, Kobara H.
    J Gastrointest Cancer 56(1): 8, 2024

  78. Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis
    Tham EKJ, Lim RY, Koh B, Tan DJH, Ng CH, Law M, Cho E, Tang NSY, Tan CS, Sim BKL, Tan EY, Lim WH, Lim MC, Nakamura T, Danpanichkul P, Chirapongsathorn S, Wijarnpreecha K, Takahashi H, Morishita A, Zheng MH, Kow A, Muthiah M, Law JH, Huang DQ.
    Clin Gastroenterol Hepatol  24: S1542-3565(24)00971-6, 2024
  79. Effects of D-Allose on experimental cardiac hypertrophy
    Akumwami S, Rahman A, Funamoto M, Hossain A, Morishita A, Ikeda Y, Kitamura H, Kitada K, Noma T, Ogino Y, Nishiyama A.
    J Pharmacol Sci 156(2): 142-148,2024
  80. Endoscopic program with a scoring system for surveillance of metachronous esophageal cell carcinoma for older patients considering risk factors after endoscopic resection
    Naito S, Fukuzawa M, Shinohara H, Kagawa Y, Madarame A, Koyama Y, Yamaguchi H, Yamauchi Y, Itoi T.
    Esophagus 21(4):530-538,2024
  81. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
    Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T.
    Oncol Lett  28(2):397,2024
  82. Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group
    Motomura K, Sasaki K, Sugii N, Yamaguchi S, Inoue H, Oshima A, Tanaka K, Otani Y, Shirahata M, Shibahara I, Nagane M, Tsuzuki S, Matsutani T, Tsukamoto Y, Kijima N, Asano K, Ohno M, Inoue A, Mineharu Y, Miyake K, Mitobe Y, Hanihara M, Kawanishi Y, Deguchi S, Saito M, Matsuda R, Ujifuku K, Arita H, Sato Y, Yamashita S, Yonezawa U, Yamaguchi J, Momii Y, Ogawa T, Kambe A, Ohba S, Fukai J, Saito N, Kinoshita M, Sumi K, Otani R, Uzuka T, Takebe N, Koizumi S, Saito R, Arakawa Y, Narita Y; Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG).
    Jpn J Clin Oncol 54(10):11,2024
  83. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.
    Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan).
    Aliment Pharmacol Ther  60(10): 1361-1373,2024
  84. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
    Arai T, Atsukawa M, Tsubota A, Oikawa T, Tada T, Matsuura K, Ishikawa T, Abe H, Kato K, Morishita A, Tani J, Okubo T, Nagao M, Iwabu M, Iwakiri K.
    Diabetes Obes Metab 26(11): 4958-4965,2024
  85. Blood pressure alteration associated with abnormal body electrolyte and water balance in
    colitis mice.
    Kundo NK, Kitada K, Fujisawa Y, Xi C, Akumwami S, Rahman MM, Seishima R, Nakamura K, Matsunaga T, Hossain A, Morishita A, Titze J, Rahman A, Nishiyama A.
    Hypertens Res 47(11): 3147-3157,2024
  86. Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
    Itokawa N, Atsukawa M, Tsubota A, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Ogawa C, Hiraoka A, Okubo H, Uojima H, Chuma M, Nozaki A, Kato K, Mikami S, Tani J, Morishita A, Tada T, Asano T, Senoh T, Oikawa T, Okubo T, Kumada T, Iwakiri K.
    Hepatol Res 54(11): 993-1003,2024
  87. Transperineal minimally invasive surgery-first approach in robot-assisted total pelvic exenteration for advanced low rectal cancer-A video vignette.
    Kondo A, Feng D, Taketani H, Oshima M, Kobara H, Okano K.
    Colorectal Dis 26(11): 2019-2020, 2024
  88. Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who underwent curative pancreatic resection after neoadjuvant chemoradiotherapy.
    Suto H, Nagao M, Matsukawa H, Fuke T, Ando Y, Oshima M, Takahashi S, Shibata T, Kamada H, Kobara H, Okuyama H, Hirao T, Kumamoto K, Okano K.
    Pancreatology 24(7): 1133-1140,2024
  89. Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
    Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group.
    Hepatol Res in press
  90. JCS/JCC/JSPCCS 2024 Guideline on Genetic Testing and Counseling in Cardiovascular Disease
    Imai Y, Kusano K, Aiba T, Ako J, Asano Y, Harada-Shiba M, Kataoka M, Kosho T, Kubo T, Matsumura T, Minamino T, Minatoya K, Morita H, Nishigaki M, Nomura S, Ogino H, Ohno S, Takamura M, Tanaka T, Tsujita K, Uchida T, Yamagishi H, Ebana Y, Fujita K, Ida K, Inoue S, Ito K, Kuramoto Y, Maeda J, Matsunaga K, Neki R, Sugiura K, Tada H, Tsuji A, Yamada T, Yamaguchi T, Yamamoto E, Kimura A, Kuwahara K, Maemura K, Minamino T, Morisaki H, Tokunaga K; Japanese Circulation Society, Japanese College of Cardiology, Japanese Society of Pediatric Cardiology and Cardiac Surgery Joint Working Group.
    Circ J  88(12): 2022-2099,2024
  91. Tofogliflozin attenuates renal lipid deposition and inflammation via PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice
    Nishihara S, Koseki M, Tanaka K, Omatsu T, Saga A, Sawabe H, Inui H, Okada T, Ohama T, Okuzaki D, Kamada Y, Ono M, Nishida M, Watanabe M, Sakata Y.
    Endocr J 30(2): 225-234,2024
  92. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting
    Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas.
    J Gastroenterol  in press
  93. A case of successful endoscopic ultrasound/endosonography-guided pancreticogastrostomy using a novel plastic stent
    Namima D, Fujisawa T, Takasaki Y, Tomishima K, Ishii S, Kobara H, Isayama H.
    Endoscopy 56(S 01): E905-E906,2024
  94. Simple use of Y-connector for proper positioning and contrast aspiration in biliary metal stent placement.
    Kobayashi K, Kobara H, Nomura T, Ogi T, Kamada H, Ono M, Masaki T.
    Endoscopy 56(S 01): E23-E24, 2024
  95. Mucosal inverted closure of a post-gastric endoscopic submucosal dissection defect using grasping forceps with good rotatability and sharp claws.
    Nakatani K, Nishiyama N, Kozuka K, Koyama Y, Matsui T, Yachida T, Kobara H.
    Endoscopy 56(S 01): E1072-E1073, 2024
  96. Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
    Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Fukushima H, Miyoshi E, Aishima S, Itoh Y, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
    Hepatol Commun 9(1): e0563, 2024
  97. Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study
    Fukunaga K, Morishita A, Imachi H, Oura K, Sato S, Kobayashi T, Saheki T, Yoshimura T, Komori K, Nakahara M, Tadokoro T, Fujita K, Tani J, Kobara H, Murao K.
    Diabetes Obes Metab in press
  98. Recurrence rate of cholecystitis after initial gallbladder stenting versus secondary gallbladder stenting: A propensity score matching study
    Nakabayashi R, Kamada H, Ono M, Kono T, Fujita N, Yamana H, Kobayashi K, Tani J, Ando Y, Suto H, Oshima M, Okano K, Kobara H.
    DEN Open 5(1):e70047, 2024
  99. Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma
    Oura K, Morishita A, Tadokoro T, Fujita K, Tani J, Kobara H.
    Int J Mol Sci 25(24) :13590, 2024
  100. Efficiency of Skeletal Muscle Mass/Weight Measurement for Distinguishing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Analysis Using InBody Bioimpedance Devices
    Tatsuta M, Masaki T, Kimura S, Sato Y, Tomida A, Ishikawa I, Nakamura Y, Takuma K, Nakahara M, Oura K, Tadokoro T, Fujita K, Tani J, Morishita A, Himoto T, Miyazaki S, Maeta T, Mori Y, Kohi F, Kobara H.
    Nutrients 16(24): 4422, 2024
  101. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
    Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, Otsuka M, Ogasawara S, George J, Chow PKH, Cai J, Shiina S, Kato N, Yokosuka O, Oura K, Yau T, Chan SL, Kuang M, Ueno Y, Chen M, Cheng AL, Cheng G, Chuang WL, Baatarkhuu O, Bi F, Dan YY, Gani RA, Tanaka A, Jafri W, Jia JD, Kao JH, Hasegawa K, Lau P, Lee JM, Liang J, Liu Z, Lu Y, Pan H, Payawal DA, Rahman S, Seong J, Shen F, Shiha G, Song T, Sun HC, Masaki T, Sirachainan E, Wei L, Yang JM, Sallano JD, Zhang Y, Tanwandee T, Dokmeci A, Zheng SS, Fan J, Fan ST, Sarin SK, Omata M.
    Hepatol Int 18(6):1661-1683, 2024
  102. The Effect of Trabeculectomy on Disc Tissue Blood Flow Across Quadrants in Open-Angle Glaucoma
    Shimazaki T, Nitta E, Nakano Y, Kobayashi N, Kojima H, Hara A, Suzuma K.
    J Glaucoma in press
  103. Prophylactic Clip Closure in Preventing Delayed Bleeding After Colorectal Endoscopic Submucosal Dissection on anticoagulants: A multicenter retrospective cohort study in Japan
    Takada K, Yoshida N, Hayashi Y, Togo D, Oka S, Fukunaga S, Morita Y, Hayashi T, Kozuka K, Tsuji Y, Murakami T, Yamamura T, Komeda Y, Takeuchi Y, Shinmura K, Fukuda H, Yoshii S, Ono S, Katsuki S, Kawashima K, Nemoto D, Yamamoto H, Saito Y, Tamai N, Tamura A.
    Endoscopy in press

脳神経内科

英文
  1. Endoscopic and clinical features of gastric emphysema
    Iwamuro M, Takenaka R, Toyokawa T, Kita M, Tsuzuki T, Yoshioka M, Gotoda T, Okanoue S, Matsubara M, Sakaguchi C, Otsuka M.
    Sci Rep 14(1):2202,2024
  2. Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the phase III randomized RAISE study.
    Utsugisawa K, Deguchi K, Konno S, Masuda M, Minami N, Murai H, Suzuki S, Suzuki S, Tsujino A, Uzawa A, Boroojerdi B, de la Borderie G, Brock M, DUDA Petra W, Vanderkelen M, Howard J. F.
    Clinical and Experimental Neuroimmunology 15(1): 45-54, 2024
  3. Reduction rate of anti-acetylcholine receptor antibody titer levels is an early prognostic indicator for myasthenia gravis.
    Hamada Y, Deguchi K, Takaba K, Kawakita R, Takata T, Morishita A, Kobara H, Masaki T.
    Neurol Clin Neurosci 12(3): 180-186, 2024
  4. Temporal expression profiles of microRNAs associated with acute phase of brain ischemia in gerbil hippocampus
    Hamada Y, Takata T, Iwama H, Kawakita R, Nonaka W, Deguchi K, Kobara H, Morishita A, Miyamoto O, Nakamura T, Itano T, Masaki T.
    Heliyon 10(7): e28875, 2024
  5. Reverse nocturnal blood pressure dipping in Parkinson’s disease is affected by physical activity but not sleep disturbances
    Deguchi K, Ikeda K, Touge T, Morishita A, Kobara H, Masaki T.
    Neurology and Clinical Neuroscience in press
  6. Anti-N-methyl-D-aspartate Receptor Encephalitis in Turner Syndrome with 45,X/46,X,idic(X)(p11.4) Mosaics.
    Kurimoto J, Kawakita R, Chiba Y, Morishita A, Masaki T, Deguchi K, Kobara H.
    Intern Med in press
  7. Multiple cutaneous focal mucinosis in a patient with atopic dermatitis
    Fujioka K, Kita M, Iwata M, Moriue T, Dainichi T.
    J Dermatol 51(9): e300-e301,2024

消化器内科

和文
  1. 亜鉛製剤の長期投与中に急激な血球減少・末梢神経障害を生じた肝硬変患者の一例
    田所智子、大浦先生、琢磨 慧、中原麻衣、藤田浩二、三村志麻、谷 丈二、森下朝洋、小野正文、樋本尚志、正木 勉
    肝臓 66(1) : 25-30, 2024
  2. 内視鏡ビッグデータとICTを活用する(第2回) 消化器内視鏡領域における遠隔診療の試み
    森田圭紀、高山弘志、鷹尾まど佳、千代大翔、西山典子、小原英幹、横川彩子、前田充毅、内多訓久
    消化器内視鏡 36(3):422-428, 2024
  3. 消化器内視鏡診療における医工連携の現状と実際
    小原英幹、小林伸也、大場晴夫
    Gastroenterological Endoscopy 66(6):1293-1306, 2024
  4. 当院における急性胆嚢炎治療の現状 経乳頭的ドレナージの有用性とコツ
    山名浩喜、鎌田英紀、中林良太、小野正大、河野寿明、藤田直樹、小林聖幸、小原英幹
    日本腹部救急医学会雑誌 44(5):679-685, 2024
  5. 第7章 肝・胆・膵 green endoscopy 消化器内視鏡診療におけるSDGsへの取り組み
    藤原新太郎、小原英幹、今川 敦
    胆と膵 Vol.45 特別号 2024 134(3): 656-660, 2024
  6. 経乳頭的胆嚢ドレナージ(ENGBD-EGBS)
    鎌田英紀、小林聖幸、山名浩喜、藤田直樹、波間大輔、河野寿明、中林良太、小野正大、小原英幹
    胆と膵 Vol.45 臨時増刊特大号 45: 1219-1224, 2024
  7. 胃・十二指腸 観察・診断 見落としの少ない十二指腸の観察法
    松井崇矩、小塚和博、小原英幹
    消化器内視鏡 Vol.36 増刊号 2024 36: 133-137, 2024
  8. 大腸 治療 切除後の創閉鎖は,こうする
    西山典子、小塚和博、小原英幹
    消化器内視鏡 Vol.36 増刊号 2024 36: 271-276, 2024
  9. 十二指腸乳頭癌をめぐる諸問題 十二指腸乳頭癌の組織学的亜型と臨床的意義
    大島 稔、浅野栄介、須藤広誠、安藤恭久、松川浩之、近藤彰宏、岸野貴賢、羽場礼次、鎌田英紀、小原英幹、岡野圭一
    胆と膵 Vol.45 特別号 2024 45: 1525-1530, 2024

脳神経内科

和文
  1. 舌咽・迷走神経麻痺による嚥下障害を主症状とした神経サルコイドーシスの1例
    濱田康宏、栗本 淳、川北梨愛、高田忠幸、伊吹英美、羽場礼次、出口一志、正木 勉
    香川県内科医会誌 60(1): 38-43, 2024